Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice.

Authors: Muñoz‐Aceituno, E., Butrón‐Bris, B., Ovejero‐Benito, M. C., Sahuquillo‐Torralba, A., Baniandrés Rodríguez, O., Herrera‐Acosta, E., Rivera‐Diaz, R., Ferran, M., Sánchez‐Carazo, J. L., Riera‐Monroig, J., Pujol‐Montcusí, J., Vidal, D., de la Cueva, P., García‐Bustinduy, M., Ruiz‐Villaverde, R., Ballescà, F., Llamas‐Velasco, M., Navares, M., Palomar‐Moreno, I., Sánchez‐García, I.

Source: Journal of the European Academy of Dermatology & Venereology; Sep2024, Vol. 38 Issue 9, p1783-1790, 8p

Subject Terms: BIOTHERAPY, SENSITIVITY & specificity (Statistics), LOGISTIC regression analysis, TREATMENT effectiveness, REGRESSION analysis

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice.

Authors: Butrón‐Bris, B., Llamas‐Velasco, M., Ovejero‐Benito, M. C., Santos‐Juanes, J., Martínez‐López, A., Ruiz‐Villaverde, R., Roustan, G., Baniandrés, O., Izu‐Belloso, R., de la Cueva, P., Sahuquillo‐Torralba, A., Gónzalez‐Quesada, A., Vilarrasa‐Rull, E., Pujol‐Montcusí, J., García‐Martínez, J., Navares, M., Palomar‐Moreno, I., Novalbos, J., Abad‐Santos, F., Daudén, E.

Source: Experimental Dermatology; Aug2024, Vol. 33 Issue 8, p1-8, 8p

Subject Terms: GENETIC polymorphisms, GENETIC variation, BIOTHERAPY, DISEASE duration